Clinical
Oncology Next Generation Sequencing: Introduction
·
Next generation sequencing for tumor and germline DNA is
required for oncology screening for therapeutic application. Rise in burden of
cancer increases the need for early detection of the condition to carry out the
generate target therapy.
·
Companies are investing to develop technologically
advanced devices/solutions for precision detection. In 2012, Oxford Nanopore
had launched the GridION sequencing platform, which can sequence a human genome
in 15 minutes. In 2012, Ion Torrent had stated that their Ion Proton benchtop
sequencer device could sequence an entire human genome in a day for less than
US$ 1,000. In November 2019, Thermo Fisher Scientific launched its fully
integrated next-generation sequencing (NGS) platform, Ion Torrent Genexus
System, featuring an automated specimen-to-report workflow that delivers
results economically in a single day.
Get a Glimpse of the In-Depth Analysis through
our Comprehensive Clinical Oncology Next Generation Sequencing Market Brochure
Key Drivers
and Restraints of Global Clinical Oncology Next Generation Sequencing Market
·
Rise in burden of cancer and its early diagnosis for
treatment is fueling market growth. According to the 2018 GLOBOCAN database,
the global cancer burden was predicted to rise to 18.1 million new cases, 9.6
million cancer deaths, and 43.8 million people living with cancer in 2018.
Majority of cancer incidences occur in Asia and about one-quarter in Europe.
·
Increase in investments for oncology research is also
driving the global clinical oncology next generation sequencing market. In
2019, Cancer Research UK invested US$ 262.90 Mn to focus on companies
developing innovative oncology treatments. As per CB Insights, a research firm,
equity investments in cancer-therapeutics startups grew from US$ 2 Bn in 2013
to US$ 4.5 Bn in 2017.
·
Non-value-based NGS reimbursement policy hampers market
growth due to relatively high total costs of delivering NGS test results
compared to other technology platforms, and limited coverage by payers
Request for Analysis of COVID19 Impact on Clinical
Oncology Next Generation Sequencing Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=74625
Targeted
Sequencing & Resequencing Technology for Skin Treatment to Witness High
Demand
·
Based on technology, the global clinical oncology next
generation sequencing market can be segmented into whole genome sequencing,
whole exome sequencing, and targeted sequencing & resequencing
·
Targeted sequencing & resequencing segment dominates
the clinical oncology next generation sequencing market, in terms of revenue
generation. This technique is useful in analyzing specific mutations. Multiple
genes can also be assessed across several samples in parallel. Due to its
cost-effective findings, and accurate and easy-to-interpret results, targeted
sequencing & resequencing holds a leading share of the global market.
AmpliSeq offered by Illumina, Inc. is a comprehensive targeted resequencing
solution, which can detect mutation in a few to hundreds of genes samples.
·
Whole genome sequencing segment is expected to grow
significantly during the forecast period. Due to decrease in sequencing
cost and expansion of computer resources, the whole genome sequencing
technology will become common and sophisticated, as it provides sufficient
information to understand the biology underlying the cancer genome and function
of unexplored non?coding regions.
Pre-Book Clinical Oncology Next Generation Sequencing Market
Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=74625<ype=S
Companion
Diagnostic Segment to Witness Rapid Growth
·
Based on application, the global clinical oncology next
generation sequencing market can be segregated into screening, companion
diagnostics, and other diagnostics. Screening segment can be further divided
into sporadic cancer and inherited cancer.
·
Demand for whole exome and genome sequencing tests is
rapidly increasing for the screening of cancer to offer targeted diagnostic and
treatment market for oncology. The next generation sequencing technology in the
field of clinical oncology is applied in genetic diagnosis, cancer classification
to prepare predictive biomarkers, and personalized medicine.
·
Companion diagnostic segment is expected to grow at a
rapid rate due to numerous benefits offered by the technology in the field of
oncology. In 2018, The Centers for Medicare & Medicaid Services (CMS)
announced that it will pay for next generation sequencing (NGS)–based companion
diagnostics for its beneficiaries with advanced cancer.
Expanding
Operations in Future? To Get the Perfect Launch Ask for a Custom Clinical
Oncology Next Generation Sequencing Market Report
North
America to Dominate Global Market for Clinical Oncology Next Generation
Sequencing
·
In terms of region, the global clinical oncology next
generation sequencing market can be divided into: North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa
·
North America holds the major share of the global market
due to rise in government initiatives investments in researches, and presence
of high-quality health care infrastructure. Furthermore, increase in incidences
of cancer and high demand for personalized medicine are likely to boost the
market in the region.
·
This market in Asia Pacific is projected to expand at a
rapid CAGR during the forecast period, owing to the clinical oncology next
generation sequencing market growth in emerging countries and continuous
development in health care and pharmaceutical industries in the region.
Countries with highest cancer rate includes Australia and New Zealand.
More Trending Reports by Transparency
Market Research:
https://www.prnewswire.com/news-releases/technological-advancements-and-innovations-to-fuel-growth-of-soft-tissue-repair-market-from-2018-to-2026-tmr-301168624.html
https://www.prnewswire.com/news-releases/global-oral-contraceptive-pills-market-projected-to-expand-at-6-cagr-rising-number-of-unplanned-pregnancies-drives-market-demand-tmr-301171827.html
About Us
“Transparency Market Research is a
next-generation market intelligence provider, offering fact-based solutions to
business leaders, consultants, and strategy professionals.
Our reports are single-point
solutions for businesses to grow, evolve, and mature. Our real-time data collection
methods along with ability to track more than one million high growth niche
products are aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision in the
shortest span of time. For organizations that require specific but
comprehensive information we offer customized solutions through adhoc reports.
These requests are delivered with the perfect combination of right sense of
fact-oriented problem solving methodologies and leveraging existing data
repositories.
TMR believes that unison of
solutions for clients-specific problems with right methodology of research is
the key to help enterprises reach right decision.”
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
